FASEB J. Pierce now sold as Thermo Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Centrella, M.
Right arrow Articles by Canalis, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Centrella, M.
Right arrow Articles by Canalis, E.

The FASEB Journal, Vol 1, 312-317, Copyright © 1987 by The Federation of American Societies for Experimental Biology

RESEARCH COMMUNICATIONS

Mitogenesis in fetal rat bone cells simultaneously exposed to type beta transforming growth factor and other growth regulators

M Centrella, TL McCarthy and E Canalis
Department of Medicine, Saint Francis Hospital, Hartford, Connecticut 06105.

Type beta transforming growth factor (TGF-beta) is found in large amounts in bone tissue, and is a potent mitogen for osteoblast-enriched cell cultures obtained from fetal rat parietal bone. Because other local and systemic factors may be presented to bone cells simultaneously with TGF-beta, it is important to understand the effects of this complex growth regulator in such circumstances. Unlike the effects observed in many tissue systems, TGF-beta does not invariably inhibit the mitogenic response of bone cells to other growth promoters. In contrast, other factors such as epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), and type alpha tumor necrosis factor (TNF-alpha) limit the response of osteoblastic bone cells to TGF-beta. TGF-beta is a much weaker mitogen for fibroblastic cells obtained from fetal rat bone, whereas fetal bovine serum, EGF, bFGF, and TNF-alpha are more potent stimulators. In addition, TGF-beta does not significantly impair the response of the fibroblastic bone cells to the other tested agents. These findings reinforce a role of TGF-beta as an anabolic bone growth regulator, and suggest that its function may be modified by other local or systemic agents that can also affect bone cells.


This article has been cited by other articles:


Home page
 EndocrinologyHome page
T. L. McCarthy, C. Ji, Y. Chen, K. Kim, and M. Centrella
Time- and Dose-Related Interactions between Glucocorticoid and Cyclic Adenosine 3',5'-Monophosphate on CCAAT/Enhancer-Binding Protein-Dependent Insulin-Like Growth Factor I Expression by Osteoblasts
Endocrinology, January 1, 2000; 141(1): 127 - 137.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
V. Gangji, S. Rydziel, B. Gabbitas, and E. Canalis
Insulin-Like Growth Factor II Promoter Expression in Cultured Rodent Osteoblasts and Adult Rat Bone
Endocrinology, May 1, 1998; 139(5): 2287 - 2292.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by The Federation of American Societies for Experimental Biology.